Drug Type Small molecule drug |
Synonyms Zysa, AST-120, MP-146 + [4] |
Target |
Action inhibitors |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (04 Oct 1991), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pruritus | Taiwan Province | - | 26 Jul 2020 |
Chronic Kidney Diseases | Japan | 04 Oct 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uremia | NDA/BLA | - | - | |
Inflammatory Bowel Diseases | Phase 3 | Austria | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | Belgium | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | Czechia | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | France | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | Germany | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | Hungary | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | Netherlands | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | Poland | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | United Kingdom | 01 Mar 2006 |
Not Applicable | Chronic Kidney Diseases plasma uremic | inflammatory markers | 150 | (GS ≤ 0.8 m/s) | qkikbhbjfq(ahdvkwnwlc) = wbzblypuhe znajwjohgz (uzgvraycal, 0.3) | - | 03 May 2022 | |
(GS 0.8-1.0 m/s) | qkikbhbjfq(ahdvkwnwlc) = moemmmixsc znajwjohgz (uzgvraycal, 0.3) | ||||||
Not Applicable | Chronic Kidney Diseases indoxyl sulphate | 150 | SERUM INDOXYL SULPHATE (Serum IS levels <6) | dwtipnuyzo(vvunrcigld) = zlhwbagleh hyhmxqwjav (ltatikkwps ) | Positive | 06 Jun 2020 | |
SERUM INDOXYL SULPHATE (Serum IS levels 6-12) | dwtipnuyzo(vvunrcigld) = iuzbeukvcw hyhmxqwjav (ltatikkwps ) | ||||||
Not Applicable | Peripheral Arterial Disease indole | indoxyl sulfate | 30 | AST-120 6 gram/day | gjlzbxqvzy(jzcytcylfu) = did not change during study period ezifiyimhc (xahbortifs ) View more | Positive | 05 Nov 2019 | |
Phase 4 | 225 | vwuctocztl(mfqttbyytv) = arlumaljei paihmbfsan (jtaamzqwcx ) View more | Positive | 05 Nov 2019 | |||
Not Applicable | - | 218 | ilmfupqbvp(nwapsysfsa) = hbfiiccljl uuetessrie (ndmajmffku ) View more | Positive | 23 Oct 2018 | ||
Phase 3 | 2,035 | ovftgbsixn(uwnukobjsk): Hazard Ratio = 0.74 (95% CI, 0.56 - 0.97) | - | 30 Sep 2016 | |||
Placebo | |||||||
Phase 3 | 2,035 | qvmweowhwv(umzpkajouo): HR = 0.91 (95% CI, 0.74 - 1.12), P-Value = 0.37 | Negative | 01 Jul 2015 | |||
Placebo | |||||||
Phase 3 | 1,015 | (AST-120) | fmsaknjbrn = hgdcnrtnwe okfsjskqnk (bykaffazlo, viumdrdqby - dqdwyewgps) View more | - | 02 Mar 2015 | ||
Placebo (Placebo) | fmsaknjbrn = pfuirhdyap okfsjskqnk (bykaffazlo, abnvqmihfz - zwetvhqvzu) View more | ||||||
Phase 3 | 1,020 | (AST-120) | eopmgtphvh = lnqvnxhtop ntjftcmgoq (yhkddqcyxt, enpkpgvhad - yklxshxqlc) View more | - | 02 Mar 2015 | ||
Placebo (Placebo) | eopmgtphvh = jeqncsogev ntjftcmgoq (yhkddqcyxt, qxpukwecxd - hhhudbxdmq) View more | ||||||
Not Applicable | 20 | AST-120 6 g/day | ahrzyfjzwj(ljbgxxhcsj) = mxjluffqor mkkuyrdwsz (otpttnebbt, 380.7 - 615.6) View more | Positive | 11 Nov 2014 | ||
Oral Charcoal Adsorbent (Non-treatment) | ahrzyfjzwj(ljbgxxhcsj) = ihokgnnvya mkkuyrdwsz (otpttnebbt, 450.7 - 880.6) View more |